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BIOETHICS FROM A PRAGMATIC PERSPECTIVE:
ETHICAL ISSUES IN BIOPHARMACEUTICALS
Michael A. Fournel*
Abstract: In recent times competitive, commercial and fiscal pressures have introduced new and challenging issues for
the pharmaceutical industry. This essay identifies some of these issues and proposes mechanisms for their resolution.
This overview is not intended to serve as a comprehensive assessment, but rather as an introduction to and call for
utilization of bioethics as a tool in the resolution of practical issues that otherwise could limit the development and
introduction of important therapeutic entities into the clinic.
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LA BIOÉTICA DESDE UNA PERSPECTIVA PRAGMÁTICA: TEMAS ÉTICOS EN LA
INDUSTRIA BIOFARMACÉUTICA
Resumen: La industria farmacéutica ha sufrido, cada vez con mayor frecuencia, presiones fiscales, de la competencia
y del comercio, que han introducido nuevos y desafiantes temas éticos. Este ensayo identifica algunos de estos temas y
propone mecanismos para resolverlos. No pretendemos que éste sea un juicio abarcador, sino que sirva, más bien, como
una introducción y un llamado para emplear a la bioética como un instrumento en la resolución de temas prácticos que,
de otra manera, podrían limitar el desarrollo y aceptación de importantes entidades terapéuticas en su aplicación clínica.
Palabras clave: industria farmacéutica, desafíos éticos, comportamiento social, desarrollo de fármacos, seguridad
A BIOÉTICA A PARTIR DE UMA PESPECTIVA PRAGMÁTICA: TEMAS ÉTICOS NA
INDUSTRIA BIOFARMACÊUTICA
Resumo: A industria farmacêutica vem sofrendo, sempre com mais frequência, pressões fiscais, da concorrência e do
comercio, que introduziram novos e desafiadores temas éticos. Este ensaio identifica alguns detes temas e propõe
mecanismos para resolvê-los. Não pretendemos que este seja um juizo abrangente, mas que sirva, como uma introdução
e um chamado para empregar a bioética como um instrumento na resolução de temas práticos que, de outra maneira,
poderiam limitar o desenvolvimento e a aceitação de importantes entidades terapêuticas em sua aplicação clínica.
Palavras chaves: industria farmacêutica, desafios éticos, comportamento social, desenvolvimento de fármacos, segurança
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The pharmaceutical industry in general, and
biopharmaceuticals specifically, is increasingly
under scrutiny to perform ethically. While this
has always been the case – indeed, the generic
term for drugs is “ethical pharmaceutical” to re-
flect the higher standards applied in the devel-
opment and eventual approval for use in humans
– in recent times competitive, commercial and
fiscal pressures have introduced new and very
challenging bioethical issues for this industry.
This essay identifies some of these issues and
proposes mechanisms for their resolution. This
overview is not intended to serve as a compre-
hensive assessment, but rather an introduction
to and call for utilization of bioethics as a tool in
the resolution of practical issues that otherwise
could limit the development and introduction of
important therapeutic entities into the clinic.
The emergence of the pharmaceutical indus-
try as a dominant commercial endeavor has been
fueled by several factors including innovation,
successes in treating life-threatening diseases and
the increasing affluence and aging of the popu-
lation. With sales in excess of US$350 billion in
2003 and multinational operations in virtually
all parts of the world, this industry touches many
lives in the discovery, development, regulation
and commercialization of its products. Regional
differences exist in all of these areas and offer
opportunities for exploitation; for example, price
controls exist in some countries but not others,
fostering potential “gray market” importation of
drugs. Some regions either lack or consciously
refuse to respect intellectual property rights, al-
lowing for generic production of drugs covered
by patents. Ethical and commercial standards are
very regional as are standards of care, all of
which present potential for misuse.
Against this background exists a need in the
pharmaceutical industry to minimize risks and
investments required for the development of new
drugs: where opportunity exists to do so there is
a compelling case to utilize such opportunities
to facilitate and even expedite drug development.
Further complicating this ethical landscape is the
evolution of ethical requirements in industrial-
ized countries, at times presenting onerous, and
not always reasonable expectations upon an in-
dustry, which is still attempting to test hypoth-
eses and failing more often than succeeding in
identifying new and novel therapies.
For purposes of discussion, the ethical issues
mentioned above can be considered to fall within
three broad categories:
Business Ethics
Examples of issues under this heading would
be commercial activities, contracts and pricing,
incentives and kickbacks, issues of good faith
and fairness, liabilities and litigation. Perhaps the
most advanced in terms of mitigation, many
mechanisms already exist to address opportuni-
ties for commercial exploitation. For example,
industry and corporate standards have been pub-
lished by most large companies and internal
mechanisms such as ethics ombudsman, active
compliance and ethics training have been estab-
lished. More importantly, companies need to
establish and vigorously defend a corporate cul-
ture and ethical philosophy to ensure compliance.
Regulatory and legal protections are also in place
in many countries, including anti-trust, competi-
tive surveillance and legislation to thwart efforts
to exploit differences. As recent problems in
other industries have illustrated, the need for
more comprehensive legislation to ensure fidu-
ciary compliance has been recognized. Con-
sumer and governmental advocacy is a major
factor influencing business to perform accord-
ing to ethical standards: the power of public ex-
posure of unethical behaviors often drives com-
panies to reform well before legislative actions
are required; oversight of the industries by gov-
ernmental agencies similarly identifies and rec-
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tifies issues. While abuses will continue to oc-
cur, this combination of self-regulation, govern-
mental controls and consumer advocacy has been
instrumental in minimizing unethical conduct.
Ethical Social Behavior
This category includes more subtle yet im-
portant aspects of ethical behavior not easily
addressed by the mechanisms discussed above.
Examples would include the openness of infor-
mation sharing, risk mitigation for patients and
customers, and local investment.
Openness of information sharing. In the past,
ownership of information generated in a clinical
trial was assumed to be exclusive to the com-
pany providing the financial support for the de-
velopment. However, this information was gath-
ered by healthcare professionals from patients
who volunteered to participate, often with little
or no remuneration and potentially subjected to
life-endangering procedures or placebo treat-
ments for their disease. Questions about data
manipulation, objectivity in assessments and rep-
resentation, and access to learnings to guide fu-
ture medical research have arisen from such re-
stricted ownership of trial results.
Risk mitigation for patients and customers.
The determination of the efficacy of a new drug
is increasingly well managed as improvements
in diagnoses, detection and understanding of
pathology is applied to clinical assessments. The
same is not the case for safety since untoward
effects may not be seen with adequate frequency
in a clinical trial setting. Relatively rare or infre-
quent adverse drug reactions may only become
evident after thousands or more uses of a given
drug. The balance between reasonable expecta-
tions for assessment of potential side effects
against desire to introduce a new therapy requires
careful consideration so as to minimize risks to
patients while maximizing the utilization of im-
portant therapeutic options.
Local investment. Also a subject under the
next category, the issue of return of the benefits
from commercialization of a drug to the com-
munities in which it was studied presents an ethi-
cal challenge since failure to do so opens the
consideration of exploitation. Yet, often the stan-
dards of care in a region make the new therapy
unaffordable to the healthcare system.
Mitigation of social behavior violations is
much more difficult since it requires primarily a
mandate from consumer and advocacy groups
for good corporate citizenship. In this regard,
patient organizations like the World Hemophilia
Foundation have been effective in requiring in-
dustry to meet minimum requirements to sup-
port and protect patients. Ultimately, the busi-
ness model requires sustainability and this drives
the need for social responsibility (Rand’s objec-
tivism is a powerful concept beyond regulation
in this regard). Industry would do well to make
investments in this arena to allow for debate and
balanced recommendations for standards and
resolution of complex issues. One such example
has been the Bayer International Bioethics Ad-
visory Council.
Ethical Drug Development
This third area represents a fascinating, evolv-
ing and important aspect of this bioethics envi-
ronment. A few examples will serve to illustrate
the category:
Use of patients in countries without intention
to market. A very controversial topic, driven by a
variety of forces, the potential for exploitation
needs to be weighed against the need to conduct
clinical trials under standards which may not be
available in all countries. For example, testing of
an already licensed drug for a new indication for
which no comprehensive medical proof exists of
efficacy yet it is already in use (so-called off-la-
bel indications) requires a placebo control. Yet, in
countries where the standard of care already in-
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cludes usage of the drug for the indication, the
medical community will consider it unethical to
subject a patient to a placebo arm. Testing in coun-
tries where this standard does not exist avoids this
ethical dilemma, but successful demonstration of
efficacy may present a financial burden to the lo-
cal health care budget.
Trial design issues. Related to the above, of-
ten drug development requires demonstration of
improvement over the existing standard of care
to justify drug licensure. In regions where that
standard is very high this represents a hurdle with
increased risk for the development versus testing
in a region with a lower standard. If the therapy
ultimately cannot be marketed in that region, the
ethical implications need to be measured against
the advance of therapeutic options for the disease.
Safety standards, quality of care. It has been
recognized for some time that exploitation of
regional differences in such regards presents ethi-
cal dilemmas yet existing standards may not be
adequate as medical research advances into pre-
viously unconsidered areas.
Post-trial treatment. If a therapy demonstrates
utility in the clinical setting, what is the obliga-
tion/expectation for the sponsor to continue to
provide access to the drug to trial participants
after the trial closes? This is especially pertinent
in those regions where eventual marketing of the
therapy is not planned or uncertain.
While some steps have been taken to estab-
lish standards for the ethical treatment of clini-
cal trial subjects (e.g., the Declaration of Helsinki
(WMA) and International Conferences on Har-
monization), many of these issues are emerging
beyond the scope of those efforts. Scientific/
medical society positions are increasingly im-
portant in this regard as are local Institutional
Ethical Committees, although these often do not
enter into the broader debate represented by some
of the issues mentioned. Most important has been
public debate of the issues, whether in sponsored
forums and scientific meetings, by patient ad-
vocacy groups or expert opinions offered by in-
stitutions like the Bayer International Bioethics
Advisory Council.
Important to all of the above is the realiza-
tion that there are inherent problems in estab-
lishing mitigation for an industry. Alignment
amongst companies is generally difficult to
achieve due to competitive pressures, often only
occurring at a lowest common denominator
level. Additionally, there are regulatory hurdles
to such cooperation, often a consequence of good
intentions to prevent negative collusion (e.g.,
anti-trust, price-fixing). The public perception
is often different, assuming all companies within
an industry have similar objectives and interac-
tions. This is fostered by media reports of ex-
ceptional behaviors that are assumed to be the
norm. Achieving a competitive advantage often
outweighs any desire for alignment since short-
term financial objectives increasingly compete
against long-term vision. As a result it is even
more imperative for industry leaders to drive the
alignment process since only they can hold these
competing forces in check. The mechanisms for
collaboration on important bioethical issues need
to be isolated from competitive pressures.
This overview of bioethical issues affecting
the pharmaceutical industry hopefully illustrates
that these issues are too significant and complex
to be left to chance for resolution. Bioethical fo-
rums need to be supported to provide the plat-
form for discussions and recommendations: they
also need to become pragmatic and practical to
have influence over current issues. It is essential
that the experts are independent from bias, so
the support for such platforms should not have
any commercial ties (i.e., public or non-commer-
cial funding). The bioethics community should
lead this effort but will likely find ready support
from allied specialties including the medical and
scientific environment.
